Cargando…
When Can We Trust Real‐World Data To Evaluate New Medical Treatments?
Concerns regarding both the limited generalizability and the slow pace of traditional randomized trials have led to calls for greater use of real‐world evidence (RWE) in the evaluation of new treatments or products. RWE studies often rely on real‐world data (RWD), including data extracted from healt...
Autores principales: | Simon, Gregory E., Bindman, Andrew B., Dreyer, Nancy A., Platt, Richard, Watanabe, Jonathan H., Horberg, Michael, Hernandez, Adrian, Califf, Robert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292968/ https://www.ncbi.nlm.nih.gov/pubmed/33932030 http://dx.doi.org/10.1002/cpt.2252 |
Ejemplares similares
-
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?
por: Simon, Gregory E., et al.
Publicado: (2021) -
When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials?
por: Watanabe, Jonathan H, et al.
Publicado: (2021) -
When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?
por: Franklin, Jessica M., et al.
Publicado: (2021) -
A Survey of Software Tool Utilization and Capabilities for Quantitative Systems Pharmacology: What We Have and What We Need
por: Ermakov, Sergey, et al.
Publicado: (2019) -
Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics
por: Ishii-Watabe, Akiko, et al.
Publicado: (2015)